Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Lowe

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Journal of Molecular Biology|December 21, 2010
Engineering a high-affinity anti-IL-15 antibody: crystal structure reveals an α-helix in VH CDR3 as key component of paratopeDavid C Lowe, Stefan Gerhardt, Alison Ward, et al.
Journal of Biomolecular Screening|December 5, 2012
Development of a homogeneous high-throughput screening assay for biological inhibitors of human rhinovirus infectionPhilip Newton, Desmond O'Shea, Edward Wells, et al.
Nature Communications|April 15, 2020
An in vivo platform to select and evolve aggregation-resistant proteinsJessica S Ebo, Janet C Saunders, Paul W A Devine, et al.
Mabs|December 9, 2014
Affinity maturation of a novel antagonistic human monoclonal antibody with a long VH CDR3 targeting the Class A GPCR formyl-peptide receptor 1Julie A Douthwaite, Sudharsan Sridharan, Catherine Huntington, et al.
Scientific Reports|February 9, 2019
Discovery and characterisation of an antibody that selectively modulates the inhibitory activity of plasminogen activator inhibitor-1Katherine A Vousden, Tomas Lundqvist, Bojana Popovic, et al.
Journal of Molecular Biology|July 5, 2011
Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokineticsDonna K Finch, Matthew A Sleeman, Jacques Moisan, et al.
Scientific Reports|June 17, 2023
Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunctionElizabeth England, D Gareth Rees, Ian Christopher Scott, et al.
Scientific Reports|December 21, 2016
Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivoClaire L Dobson, Paul W A Devine, Jonathan J Phillips, et al.
Nature Communications|September 15, 2015
Oxidation of the alarmin IL-33 regulates ST2-dependent inflammationE Suzanne Cohen, Ian C Scott, Jayesh B Majithiya, et al.
Mabs|December 31, 2015
The INNs and outs of antibody nonproprietary namesTim D Jones, Paul J Carter, Andreas Plückthun, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal of Molecular Biology|December 21, 2010
Engineering a high-affinity anti-IL-15 antibody: crystal structure reveals an α-helix in VH CDR3 as key component of paratopeDavid C Lowe, Stefan Gerhardt, Alison Ward, et al.
Journal of Biomolecular Screening|December 5, 2012
Development of a homogeneous high-throughput screening assay for biological inhibitors of human rhinovirus infectionPhilip Newton, Desmond O'Shea, Edward Wells, et al.
Nature Communications|April 15, 2020
An in vivo platform to select and evolve aggregation-resistant proteinsJessica S Ebo, Janet C Saunders, Paul W A Devine, et al.
Mabs|December 9, 2014
Affinity maturation of a novel antagonistic human monoclonal antibody with a long VH CDR3 targeting the Class A GPCR formyl-peptide receptor 1Julie A Douthwaite, Sudharsan Sridharan, Catherine Huntington, et al.
Scientific Reports|February 9, 2019
Discovery and characterisation of an antibody that selectively modulates the inhibitory activity of plasminogen activator inhibitor-1Katherine A Vousden, Tomas Lundqvist, Bojana Popovic, et al.
Journal of Molecular Biology|July 5, 2011
Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokineticsDonna K Finch, Matthew A Sleeman, Jacques Moisan, et al.
Scientific Reports|June 17, 2023
Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunctionElizabeth England, D Gareth Rees, Ian Christopher Scott, et al.
Scientific Reports|December 21, 2016
Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivoClaire L Dobson, Paul W A Devine, Jonathan J Phillips, et al.
Nature Communications|September 15, 2015
Oxidation of the alarmin IL-33 regulates ST2-dependent inflammationE Suzanne Cohen, Ian C Scott, Jayesh B Majithiya, et al.
Mabs|December 31, 2015
The INNs and outs of antibody nonproprietary namesTim D Jones, Paul J Carter, Andreas Plückthun, et al.
Pageof 2